Glasson S, Zini R, Tillement J P
Biochem Pharmacol. 1982 Mar 1;31(5):831-5. doi: 10.1016/0006-2952(82)90470-1.
The binding of two drugs, ticlopidine and PCR 2362, chemically related to thienopyridin, potent antiaggregant agents, was studied in vitro to serum and to the corresponding isolated proteins, HSA, alpha 1-AGP, VLDL, LDL and HDL, using equilibrium dialysis at pH 7.4 and 37 degrees. The binding of these drugs to HSA and lipoproteins was non-saturable. The binding capacity of the lipoproteins was much greater than that of HSA and appeared to be dependent on lipid content. The binding capacities of the apoproteins were less than 10% of that observed for the native lipoproteins suggesting that drug-lipoprotein binding involves drug solubilization in the lipid phase of lipoproteins rather than a classical binding to definite sites. However drug binding to alpha 1-AGP was saturable with n = 3 for both and K = 89,000 and 33,000 for ticlopidine and PCR 2362, respectively. At physiological concentration, alpha 1-AGP binding capacity represented 15% of total serum binding capacity which could double in pathological states, in which the level of this protein is increased.
研究了与噻吩并吡啶化学相关的两种强效抗聚集剂药物噻氯匹定和PCR 2362在体外与血清以及相应分离出的蛋白质(人血清白蛋白、α1-抗胰蛋白酶、极低密度脂蛋白、低密度脂蛋白和高密度脂蛋白)的结合情况,实验在pH 7.4和37摄氏度条件下采用平衡透析法进行。这些药物与人血清白蛋白和脂蛋白的结合是不饱和的。脂蛋白的结合能力远大于人血清白蛋白,且似乎取决于脂质含量。载脂蛋白的结合能力不到天然脂蛋白的10%,这表明药物与脂蛋白的结合涉及药物在脂蛋白脂质相中的溶解,而非与特定位点的经典结合。然而,药物与α1-抗胰蛋白酶的结合是饱和的,噻氯匹定和PCR 2362的n值均为3,K值分别为89,000和33,000。在生理浓度下,α1-抗胰蛋白酶的结合能力占血清总结合能力的15%,在该蛋白水平升高的病理状态下,这一比例可能翻倍。